Epitalon

Epitalon, also written Epithalon, is the tetrapeptide Ala-Glu-Asp-Gly (AEDG), composed of L-amino acids joined through α-peptide bonds. It was developed on the basis of the amino-acid composition of epithalamin, a bovine pineal-gland polypeptide extract, and was reported to have been detected in a physiological pineal extract in 2017.

Because it has three asymmetric centres, the molecule exists as eight stereoisomers, of which only the all-L form is the naturally occurring one. Published work has used the free base as well as acetate and trifluoroacetate salts.

Mechanism

The best-known mechanistic finding is a cell-culture result. In telomerase-negative human fetal fibroblast culture, addition of the peptide was associated with expression of the catalytic subunit of telomerase, enzymatic telomerase activity, and telomere elongation, which the authors attributed to possible reactivation of the telomerase gene in somatic cells.

Beyond that, the mechanism remains open. A 2025 review states that the precise mechanism of action remains unverified and unclear and identifies no confirmed receptor for the peptide. The wider literature it surveys is drawn from in vitro systems, mice, rats, Drosophila melanogaster, rhesus monkeys, rabbits, frogs and bovine cells and embryos; an older indexed report examined the parent extract epithalamin and lifespan and pineal and serum melatonin levels in old rats.

Evidence status

Epitalon is not an approved medicine anywhere described in the sources consulted. The 2025 review refers to approval only as a future possibility, stating that additional short- and long-term toxicity studies would be essential before approval as an active pharmaceutical ingredient, and it identifies no marketing authorisation, approved indication or regulatory agency. The same review reports that products labelled as containing Epitalon were analysed as illegal pharmaceutical preparations.

Human evidence is minimal. The review limits it to described clinical studies in retinitis pigmentosa and circadian-rhythm regulation, and states that it does not report whether those studies were randomised, blinded or conducted under a formal trial-phase structure, nor is long-term human follow-up provided for either.

What the literature does not establish

• The telomerase and telomere-elongation finding is a result in human fetal fibroblast culture; the review states there are no human data for telomerase activation in vivo.
• No confirmed receptor or verified mechanism of action has been established.
• Effects reported in animals and cell models — lifespan extension, tumour suppression, retinal protection, endocrine regulation — are not established as clinically meaningful human benefits.
• Human pharmacokinetics, bioavailability, tissue distribution, metabolism and elimination are not established.
• The pharmacological properties of the seven non-natural stereoisomers, and the effects of the different salt forms, have not been comparatively evaluated.

Sources

• Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells (PubMed) — establishes that the telomerase and telomere findings were obtained in telomerase-negative human fetal fibroblast culture, with no receptor, human in vivo, or regulatory information.
• Overview of Epitalon — a highly bioactive pineal tetrapeptide (PMC) — establishes the AEDG sequence, stereochemistry, derivation from epithalamin, the unverified mechanism, the absence of approval, and the limits of the human evidence.
• Effect of pineal peptide preparation (epithalamin) on life span and melatonin level in old rats (PubMed) — the indexed record of the rat lifespan and melatonin study of the parent pineal extract; no abstract is available and no human data are reported.